{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:20Z","timestamp":1792784600231,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Actelion Pharmaceuticals Ltd."}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.12.001","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T02:21:55Z","timestamp":1449109315000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug\u2013drug interactions"],"prefix":"10.1016","volume":"117","author":[{"given":"Jeanine","family":"Utz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.M.","family":"van Giersbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2015.12.001_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme replacement in Gaucher disease","volume":"1","author":"Beutler","year":"2004","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","article-title":"Gaucher disease","volume":"4","author":"Nagral","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"4","key":"10.1016\/j.ymgme.2015.12.001_bb0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0404.2006.00774.x","article-title":"Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?","volume":"115","author":"Halperin","year":"2007","journal-title":"Acta Neurol. Scand."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2015.12.001_bb0025","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/ajh.24057","article-title":"Gaucher disease and comorbidities: B-cell malignancy and parkinsonism","volume":"90","author":"Cox","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.ymgme.2015.12.001_bb0030","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.ymgme.2015.12.001_bb0035","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2012.e21","article-title":"Bone turnover markers in patients with type 1 Gaucher disease","volume":"4","author":"Giuffrida","year":"2012","journal-title":"Hematology Reports"},{"issue":"12","key":"10.1016\/j.ymgme.2015.12.001_bb0040","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ymgme.2015.12.001_bb0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/jnnp.2006.111518","article-title":"Neurological evaluation of patients with Gaucher disease diagnosed as type 1","volume":"79","author":"Capablo","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.ymgme.2015.12.001_bb0050","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0055","series-title":"CERDELGA\u2122 (Eliglustat) Capsules: Full Prescribing Information","author":"FDA","year":"2014"},{"issue":"6","key":"10.1016\/j.ymgme.2015.12.001_bb0060","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","article-title":"Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease","volume":"138","author":"Hughes","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0065","series-title":"GeneReviews\u00ae","article-title":"Gaucher disease","author":"Pastores","year":"1993"},{"issue":"8","key":"10.1016\/j.ymgme.2015.12.001_bb0070","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1101\/gr.103341.109","article-title":"Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver","volume":"20","author":"Yang","year":"2010","journal-title":"Genome Res."},{"issue":"6","key":"10.1016\/j.ymgme.2015.12.001_bb0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bcpt.12355","article-title":"Drug\u2013drug interaction between Losartan and Paclitaxel in human liver microsomes with different CYP2C8 genotypes","volume":"116","author":"Mukai","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.ymgme.2015.12.001_bb0080","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","article-title":"Applications of CYP450 testing in the clinical setting","volume":"17","author":"Samer","year":"2013","journal-title":"Molecular Diagnosis & Therapy"},{"key":"10.1016\/j.ymgme.2015.12.001_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.apha.2014.06.009","article-title":"P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery","volume":"71","author":"Davis","year":"2014","journal-title":"Adv. Pharmacol. (San Diego, Calif)"},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bse0500161","article-title":"The P-glycoprotein multidrug transporter","volume":"50","author":"Sharom","year":"2011","journal-title":"Essays Biochem."},{"issue":"11","key":"10.1016\/j.ymgme.2015.12.001_bb0100","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1016\/j.bbagen.2013.06.038","article-title":"Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR)","volume":"1830","author":"Rauch","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2015.12.001_bb0105","unstructured":"U.S. Department of Health and Human Services FaDAF, Center for Drug Evaluation and Research (CDER). Guidance for industry: drug interaction studies \u2014 study design, data analysis, implications for dosing, and labeling recommendations. Rockville, MD; 2012. p. 75."},{"issue":"8","key":"10.1016\/j.ymgme.2015.12.001_bb9000","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11910-013-0368-x","article-title":"The association between ss-glucocerebrosidase mutations and parkinsonism","volume":"13","author":"Swan","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"6","key":"10.1016\/j.ymgme.2015.12.001_bb0115","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12335","article-title":"Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature","volume":"161","author":"Arends","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1476-511X-9-113","article-title":"Sphingolipids: the nexus between Gaucher disease and insulin resistance","volume":"9","author":"Fuller","year":"2010","journal-title":"Lipids Health Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2015.12.001_bb0125","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/pds.3760","article-title":"Results from a 9-year Intensive Safety Surveillance Scheme (IS(3)) in miglustat (Zavesca(\u00ae))-treated patients","volume":"24","author":"Brand","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10545-006-0154-x","article-title":"Psychological complications of patients with Gaucher disease","volume":"29","author":"Packman","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2015.12.001_bb0140","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4065\/mcp.2009.0278","article-title":"Warfarin sensitivity genotyping: a review of the literature and summary of patient experience","volume":"84","author":"Moyer","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-14-50","article-title":"CYP1A2 polymorphism \u22121545C>T (rs2470890) is associated with increased side effects to clozapine","volume":"14","author":"Viikki","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"9","key":"10.1016\/j.ymgme.2015.12.001_bb0150","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1248\/bpb.b14-00366","article-title":"Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro","volume":"37","author":"Mukai","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CE.S20201","article-title":"An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease","volume":"7","author":"Hollak","year":"2012","journal-title":"Core Evidence"},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0160","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/00498250601094543","article-title":"The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat","volume":"37","author":"Treiber","year":"2007","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"key":"10.1016\/j.ymgme.2015.12.001_bb0165","unstructured":"FDA. Zavesca: Full prescribing information. 2014."},{"issue":"5","key":"10.1016\/j.ymgme.2015.12.001_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","article-title":"Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers","volume":"51","author":"Peterschmitt","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.ymgme.2015.12.001_bb0175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0091270003256059","article-title":"Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice","volume":"43","author":"Veronese","year":"2003","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ymgme.2015.12.001_bb0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","article-title":"Drug\u2013drug interactions mediated through P-glycoprotein: clinical relevance and in vitro\u2013in vivo correlation using digoxin as a probe drug","volume":"85","author":"Fenner","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-8587(13)70045-7","article-title":"Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives","volume":"1","author":"Seibel","year":"2013","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","article-title":"Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy","volume":"18","author":"Weinreb","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1172-7-12","article-title":"Gaucher disease and the synucleinopathies: refining the relationship","volume":"7","author":"Campbell","year":"2012","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bcmd.2010.10.007","article-title":"A monozygotic twin pair with highly discordant Gaucher phenotypes","volume":"46","author":"Biegstraaten","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-7075-10-34","article-title":"Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review","volume":"10","author":"Doneda","year":"2013","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.ymgme.2015.12.001_bb0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4614-0650-1_7","article-title":"Glycosphingolipids and insulin resistance","volume":"721","author":"Aerts","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.ymgme.2015.12.001_bb0215","first-page":"801","article-title":"Gauchers disease presenting with portal hypertension","volume":"48","author":"Bandyopadhyay","year":"2011","journal-title":"Indian Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0220","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10545-011-9313-9","article-title":"Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy","volume":"34","author":"Lo","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2015.12.001_bb0225","first-page":"191","article-title":"Echocardiographic assessment in children with Gaucher disease receiving enzyme replacement therapy","volume":"12","author":"Ayyildiz","year":"2012","journal-title":"Anadolu kardiyoloji dergisi: AKD"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2015.12.001_bb0230","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1007\/s10545-009-1207-8","article-title":"IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report","volume":"32","author":"Martinez-Redondo","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2015.12.001_bb0235","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000108802","article-title":"Subdural empyema in a case of Gaucher disease: a rare presentation","volume":"43","author":"Garg","year":"2007","journal-title":"Pediatr. Neurosurg."},{"issue":"1","key":"10.1016\/j.ymgme.2015.12.001_bb0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcmd.2010.10.008","article-title":"Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil","volume":"46","author":"Doneda","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2015.12.001_bb0245","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00042737-200506000-00015","article-title":"Menetrier's disease presenting as an acute protein-losing gastroenteropathy in a 27-year-old man with Gaucher disease","volume":"17","author":"Brautbar","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.ymgme.2015.12.001_bb0250","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/BF03021780","article-title":"Uncomplicated outcome after anesthesia for pediatric patients with Gaucher disease","volume":"52","author":"Ioscovich","year":"2005","journal-title":"Can. J. Anaesth."},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S026502150524228X","article-title":"Anaesthesia for total hip replacement in Gaucher's disease","volume":"23","author":"Ioscovich","year":"2006","journal-title":"Eur. J. Anaesthesiol."},{"issue":"3","key":"10.1016\/j.ymgme.2015.12.001_bb0260","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPH.0b013e3182050945","article-title":"Long-term adaptive functioning outcomes of children with inherited metabolic and genetic diseases treated with hematopoietic stem cell transplantation in a single large pediatric center: parents' perspective","volume":"33","author":"Gassas","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921530086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921530086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T02:56:29Z","timestamp":1537152989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921530086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S109671921530086X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.12.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug\u2013drug interactions","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}